Understanding the Anti-inflammatory Activity of Second-Generation H1 Antihistamines

Antihistamines target the histamine H1 receptor. The affinity of this interaction defines their activity and, more importantly, their adverse effects. In recent years, however, some antihistamines have demonstrated a direct influence on inflammatory events, aside from their antiallergic properties. Although still unclear, these effects seem both H1 receptor-dependent and -independent. The available evidence reveals that some antihistamines have a role in early-phase reactions through the inhibition of the release of mediators such as histamine and tryptase but may also modulate late-phase allergic reactions by inhibiting eosinophil and neutrophil chemotaxis, activation, and survival. While some antihistamines have shown efficacy in reducing cytokine levels and inflammatory cell migration, these effects are often achieved at supratherapeutic doses, limiting their clinical application. Rupatadine, a second-generation antihistamine, has demonstrated broad inhibitory effects on several proinflammatory cytokines, such as IL-5, IL-6, IL-8, TNF-a, and GM-CSF. More importantly, there is evidence of a dual role for rupatadine, being both an H1 receptor antagonist and a PAF inhibitor. In this sense, the MASPAF study was essential in demonstrating the anti-PAF activity of rupatadine in human mast cells, with subsequent studies confirming its efficacy in both allergic rhinitis and chronic spontaneous urticaria. The aim of this narrative review is to summarize the available evidence on currently prescribed antihistamines, focusing on their mechanism of action and potential anti-inflammatory effects.

Authors

Institutions

Publication Details

Journal
Journal of Investigational Allergology and Clinical Immunology
Published
2026-11-17
DOI
https://doi.org/10.18176/jiaci.1201
Primary Topic
Mast cells and histamine
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Understanding the Anti-inflammatory Activity of Second-Generation H1 Antihistamines

Joan Bartra, Alberto García de la Fuente, Patricia Mir‐Ihara, Sofia Carreras Kàtcheff et al.
Journal of Investigational Allergology and Clinical Immunology
Mast cells and histamine
article

Understanding the Anti-inflammatory Activity of Second-Generation H1 Antihistamines

Joan Bartra, Alberto García de la Fuente, Patricia Mir‐Ihara, Sofia Carreras Kàtcheff, Rosa Muñoz‐Cano, Carlota Badía-Santolaria
article en

Abstract

Antihistamines target the histamine H1 receptor. The affinity of this interaction defines their activity and, more importantly, their adverse effects. In recent years, however, some antihistamines have demonstrated a direct influence on inflammatory events, aside from their antiallergic properties. Although still unclear, these effects seem both H1 receptor-dependent and -independent. The available evidence reveals that some antihistamines have a role in early-phase reactions through the inhibition of the release of mediators such as histamine and tryptase but may also modulate late-phase allergic reactions by inhibiting eosinophil and neutrophil chemotaxis, activation, and survival. While some antihistamines have shown efficacy in reducing cytokine levels and inflammatory cell migration, these effects are often achieved at supratherapeutic doses, limiting their clinical application. Rupatadine, a second-generation antihistamine, has demonstrated broad inhibitory effects on several proinflammatory cytokines, such as IL-5, IL-6, IL-8, TNF-a, and GM-CSF. More importantly, there is evidence of a dual role for rupatadine, being both an H1 receptor antagonist and a PAF inhibitor. In this sense, the MASPAF study was essential in demonstrating the anti-PAF activity of rupatadine in human mast cells, with subsequent studies confirming its efficacy in both allergic rhinitis and chronic spontaneous urticaria. The aim of this narrative review is to summarize the available evidence on currently prescribed antihistamines, focusing on their mechanism of action and potential anti-inflammatory effects.

Journal of Investigational Allergology and Clinical ImmunologyVol. 36(6)
Instituto de Salud Carlos III (ES), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (ES), Hospital Clínic de Barcelona (ES), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Instituto de Investigación de Enfermedades Raras (ES), Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (ES), Universitat de Barcelona (ES)
Good health and well-being
Mast cells and histamine
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon